サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468145

インフルエンザ診断市場レポート：製品、試験タイプ、インフルエンザタイプ、エンドユーザー、地域別、2024～2032年

Influenza Diagnostics Market Report by Product, Test Type, Type of Flu, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
インフルエンザ診断市場レポート：製品、試験タイプ、インフルエンザタイプ、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のインフルエンザ診断市場規模は、2023年に9億5,200万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに15億9,400万米ドルに達し、2024～2032年の間に5.7%の成長率（CAGR）を示すと予測しています。ワクチン接種の増加、ポイント・オブ・ケア試験の利便性、インフルエンザウイルスに関する調査の増加、公衆衛生プログラムによる認知度の向上などが、市場を推進している要因の一部です。

一般にインフルエンザとして知られるインフルエンザは、主に鼻、喉、肺を含む呼吸器系を標的とするウイルス感染症です。インフルエンザ診断には、呼吸器系サンプル内のインフルエンザAとBウイルス核タンパク質抗原の存在を同定するために設計された一連の免疫測定試験が含まれます。診断法には、迅速抗原試験、逆転写ポリメラーゼ連鎖反応（RT-PCR）、免疫蛍光アッセイ、血清学的試験、迅速分子アッセイなどがあります。医療関係者は、これらの試験によってインフルエンザ株を迅速に検出し、分類することで、効果的な治療法の決定や公衆衛生管理に役立てています。診断技術の絶え間ない進化と、インフルエンザウイルスに関する継続的な研究により、これらの試験の効率と信頼性は向上しています。医療プロバイダーが季節性インフルエンザの流行やパンデミックの可能性と闘うために努力している中、正確な診断は迅速な介入と情報に基づいた医療戦略を可能にする礎石であり続けています。

世界市場の主要原動力は、インフルエンザ流行の増加です。これに伴い、潜在的なパンデミックに対する世界の懸念の高まりが診断能力への投資を促進し、市場に大きく貢献しています。さらに、急速な技術革新が診断試験の精度とスピードを向上させ、市場にプラスの影響を与えています。これとは別に、国民の意識向上キャンペーンが活発化していることも、タイムリーな試験を求める個人を増やし、市場を活性化しています。さらに、医療支出の増加は、先進的な診断方法の採用をサポートし、市場を促進しています。加えて、高齢者は重症のインフルエンザにかかりやすく、診断の需要を押し上げています。さらに、都市人口の増加は感染率の上昇に寄与しており、確実な診断法が必要とされています。頻繁な旅行はインフルエンザの蔓延を加速させるため、効率的な診断が必要となります。そのため、市場には多くのビジネス機会がもたらされています。

インフルエンザ診断市場の動向と促進要因：

医療への容易なアクセス

医療へのアクセスが容易であることが市場の成長を促しています。医療機関へのアクセスが改善されたことで、インフルエンザ感染の診断試験をタイムリーに受ける人が増えています。医療サービスに容易にアクセスできるようになると、人々は症状の発現時に試験を受ける傾向が強まり、早期発見と適切な介入につながります。このタイムリーなアプローチは、ウイルスの蔓延を防ぐだけでなく、患者の予後を改善することにもつながります。さらに、医療施設への便利なアクセスは、大規模な試験インフラを必要とせずに迅速な結果を提供するポイントオブケア試験など、さまざまな診断方法の採用を支えています。このようにアクセスしやすい医療環境は、診断メーカー、医療提供者、患者にとって良好なエコシステムを構築し、最終的に市場成長に寄与しています。

慢性疾患の増加

いくつかの慢性疾患の有病率の増加が市場を活性化しています。糖尿病、心血管障害、呼吸器疾患などの慢性疾患は免疫系を弱め、重症のインフルエンザ感染症にかかりやすくします。こうした慢性疾患に罹患する患者数が増加するにつれて、正確で早期のインフルエンザ診断に対する需要が高まっています。慢性疾患患者はインフルエンザによる合併症のリスクが高いため、迅速な発見と適切な医療介入が必要となります。医療プロバイダーは、潜在的な合併症を軽減し、タイムリーな治療を提供するために、このような脆弱な集団の試験を優先します。さらに、慢性疾患とインフルエンザは相互に関連しているため、包括的な診断アプローチの必要性が強調されています。既往症のある人の正確なインフルエンザ診断により、医療専門家は治療計画を調整し、合併症を効果的に管理し、患者の転帰を改善することができます。慢性疾患が世界的に増加し続ける中、インフルエンザ診断に対する需要は、基礎疾患を持つ人々の健康を守るために不可欠なものとなっています。この継続的な需要は市場に大きく貢献しています。

人工知能の急速な統合

人工知能（AI）の急速な統合が市場に好影響を与えています。AI技術は、インフルエンザの検出精度、スピード、効率を高めることで診断能力に革命をもたらしています。AIを搭載したアルゴリズムは、患者の病歴、症状、試験結果など、さまざまな情報源から得られる膨大な量のデータを分析し、より正確でカスタマイズ型診断洞察を提供することができます。これにより、インフルエンザ患者の特定が加速され、タイムリーな医療介入や公衆衛生対応が可能になります。機械学習とAIのアルゴリズムは、インフルエンザ発生の予測モデリングも改善します。過去のデータ、パターン、環境要因を分析することで、これらの技術は潜在的なインフルエンザの流行を予測し、医療組織が効果的に準備し、リソースを配分するのを支援します。さらに、AIを活用した画像解析は、胸部X線などの医療画像を評価して、インフルエンザに関連する合併症を特定し、病気の進行を正確にモニターするのに役立ちます。AI統合の急速なペースは、診断の状況を一変させ、より多くの情報に基づいた意思決定と正確な患者ケアのための高度なツールを医療専門家に提供しています。この動向は市場に大きく貢献しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 インフルエンザ診断の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 試験キット・試薬
  • 試験機器
  • その他

第7章 市場内訳：試験タイプ別

  • 分子診断
    • 市場動向
    • 主要セグメント
      • ポリメラーゼ連鎖反応
      • 等温核酸増幅試験
      • その他の分子試験
    • 市場予測
  • 従来の診断試験
    • 市場動向
    • 主要セグメント
      • インフルエンザ迅速診断試験
      • ウイルス培養試験
      • 直接蛍光抗体試験
      • 血清学的試験
    • 市場予測

第8章 市場内訳：インフルエンザタイプ別

  • A型インフルエンザ
  • B型インフルエンザ
  • C型インフルエンザ

第9章 市場内訳：エンドユーザー別

  • 病院
  • 診断ラボ
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Coris Bioconcept
    • Danaher Corporation
    • DiaSorin S.p.A.
    • F. Hoffmann-La Roche Ltd（Roche Holding AG）
    • Hologic Inc.
    • Meridian Bioscience Inc.
    • Qiagen N.V
    • Quidel Corporation
    • Sekisui Diagnostics LLC（Sekisui Medical Co. Ltd.）
    • Siemens Healthineers AG（Siemens AG）
図表

List of Figures

  • Figure 1: Global: Influenza Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Diagnostics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Influenza Diagnostics Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Influenza Diagnostics Market: Breakup by Test Type (in %), 2023
  • Figure 6: Global: Influenza Diagnostics Market: Breakup by Type of Flu (in %), 2023
  • Figure 7: Global: Influenza Diagnostics Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Influenza Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Influenza Diagnostics (Test Kit and Reagents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Influenza Diagnostics (Test Kit and Reagents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Influenza Diagnostics (Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Influenza Diagnostics (Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Influenza Diagnostics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Influenza Diagnostics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Influenza Diagnostics (Molecular Diagnostic Tests) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Influenza Diagnostics (Molecular Diagnostic Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Influenza Diagnostics (Traditional Diagnostic Tests) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Influenza Diagnostics (Traditional Diagnostic Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Influenza Diagnostics (Type A Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Influenza Diagnostics (Type A Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Influenza Diagnostics (Type B Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Influenza Diagnostics (Type B Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Influenza Diagnostics (Type C Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Influenza Diagnostics (Type C Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Influenza Diagnostics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Influenza Diagnostics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Influenza Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Influenza Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Influenza Diagnostics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Influenza Diagnostics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia-Pacific: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia-Pacific: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: Influenza Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 79: Middle East and Africa: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Influenza Diagnostics Industry: SWOT Analysis
  • Figure 81: Global: Influenza Diagnostics Industry: Value Chain Analysis
  • Figure 82: Global: Influenza Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Diagnostics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Influenza Diagnostics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Influenza Diagnostics Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 4: Global: Influenza Diagnostics Market Forecast: Breakup by Type of Flu (in Million US$), 2024-2032
  • Table 5: Global: Influenza Diagnostics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Influenza Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Influenza Diagnostics Market: Competitive Structure
  • Table 8: Global: Influenza Diagnostics Market: Key Players
目次
Product Code: SR112024A6053

The global influenza diagnostics market size reached US$ 952.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,594.0 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032. The increasing vaccination efforts, the convenience of point-of-care tests, the rising research into flu viruses, and the growing awareness through public health programs are some of the factors propelling the market.

Influenza, commonly known as the flu, is a viral infection primarily targeting the respiratory system, encompassing the nose, throat, and lungs. Influenza diagnostics encompasses an array of immunoassay tests designed to identify the presence of influenza A and B viral nucleoprotein antigens within respiratory samples. Among the diagnostic options available are rapid antigen testing, reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assays, serology, and rapid molecular assays. The medical fraternity relies on these tests to detect and categorize influenza strains promptly, aiding in effective treatment decisions and public health management. The continual evolution of diagnostic techniques and the ongoing research into influenza viruses enhance the efficiency and reliability of these tests. As healthcare providers strive to combat seasonal flu outbreaks and potential pandemics, accurate diagnostics remain a cornerstone, enabling swift intervention and informed medical strategies.

The global market is majorly driven by the increasing occurrence of flu outbreaks. In line with this, the rising global concerns about potential pandemics drive investments in diagnostic capabilities, significantly contributing to the market. Furthermore, rapid technological innovations improve the accuracy and speed of diagnostic tests, positively influencing the market. Apart from this, the growing public awareness campaigns encourage more individuals to seek timely testing, catalyzing the market. Moreover, the escalating healthcare spending supports the adoption of advanced diagnostic methods, propelling the market. Besides, elderly individuals are more susceptible to severe flu, boosting demand for diagnostics. Additionally, the increasing urban populations contribute to higher infection rates, requiring robust diagnostics. Frequent travel accelerates the spread of the flu, necessitating efficient diagnostics. This, in turn, offers numerous opportunities for the market.

Influenza Diagnostics Market Trends/Drivers:

Easy access to healthcare

The easy access to healthcare is stimulating market growth. Improved accessibility to medical facilities encourages individuals to seek timely diagnostic testing for flu infections. When healthcare services are easily reachable, people are more inclined to undergo testing at the onset of symptoms, leading to early detection and appropriate intervention. This timely approach not only aids in preventing the spread of the virus but also facilitates better patient outcomes. Furthermore, convenient access to healthcare facilities supports the adoption of various diagnostic methods, including point-of-care testing, which provides rapid results without requiring extensive laboratory infrastructure. This accessible healthcare environment creates a favorable ecosystem for diagnostic manufacturers, healthcare providers, and patients, ultimately contributing to market growth.

Increasing prevalence of several chronic diseases

The increasing prevalence of several chronic diseases is catalyzing the market. Chronic diseases, such as diabetes, cardiovascular disorders, and respiratory conditions, weaken the immune system and make individuals more susceptible to severe flu infections. As the number of individuals affected by these chronic conditions rises, the demand for accurate and early influenza diagnostics intensifies. Patients with chronic diseases are at a higher risk of complications from the flu, necessitating prompt detection and tailored medical interventions. Healthcare providers prioritize testing these vulnerable populations to mitigate potential complications and provide timely treatment. Moreover, the interconnectedness of chronic diseases and flu underscores the need for comprehensive diagnostic approaches. Accurate flu diagnosis in individuals with pre-existing conditions enables healthcare professionals to tailor treatment plans, manage complications effectively, and improve patient outcomes. As chronic diseases continue to increase globally, the demand for influenza diagnostics becomes integral in safeguarding the health of individuals with underlying conditions. This ongoing demand significantly contributes to the market.

Rapid integration of artificial intelligence

The rapid integration of artificial intelligence (AI) is favorably impacting the market. AI technologies are revolutionizing diagnostic capabilities by enhancing flu detection accuracy, speed, and efficiency. AI-powered algorithms can analyze vast amounts of data from various sources, including patient histories, symptoms, and test results, to provide more precise and tailored diagnostic insights. This accelerates the identification of flu cases, enabling timely medical interventions and public health responses. Machine learning and AI algorithms also improve predictive modeling for flu outbreaks. By analyzing historical data, patterns, and environmental factors, these technologies aid in forecasting potential flu epidemics, assisting healthcare organizations in preparing and allocating resources effectively. Additionally, AI-driven image analysis assists in evaluating medical images, such as chest X-rays, to identify flu-related complications and monitor disease progression accurately. The rapid pace of AI integration is transforming the diagnostic landscape, offering healthcare professionals advanced tools for more informed decision-making and precise patient care. This trend contributes significantly to the market.

Influenza Diagnostics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, test type, type of flu and end user.

Breakup by Product:

Test Kit and Reagents

Instruments

Others

Test Kit and Reagents dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes test kit and reagents, instruments, and others. According to the report, test kit and reagents represented the largest segment.

Test kit and reagents form the foundation of diagnostic procedures, providing the necessary chemical components for identifying viral antigens and antibodies in patient samples. These kits enable healthcare professionals to swiftly and accurately diagnose influenza infections, facilitating timely medical interventions and public health responses. The continuous innovation in test kit technology, including improved sensitivity and specificity, contributes to heightened accuracy in flu detection.

On the other hand, instruments encompass the equipment for processing and analyzing samples, automating diagnostic workflows, and delivering reliable results. These instruments, ranging from PCR machines to automated immunoassay platforms, streamline the testing process, reduce human errors, and enhance the overall efficiency of diagnostics.

Breakup by Test Type:

Molecular Diagnostic Tests

Polymerase Chain Reaction

Isothermal Nucleic Acid Amplification Tests

Other Molecular Tests

Traditional Diagnostic Tests

Rapid Influenza Diagnostic Tests

Viral Culture Tests

Direct Fluorescent Antibody Test

Serological Tests

Traditional Diagnostic Test dominates the market

The report has provided a detailed breakup and analysis of the market based on the test type. This includes molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests, other molecular tests) and traditional diagnostic tests (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests). According to the report, traditional diagnostic tests represented the largest segment.

Traditional diagnostic tests encompass methods like rapid antigen testing and immunofluorescence assays. While they may not offer the same level of sensitivity as molecular tests, they provide rapid results, making them invaluable in scenarios where swift diagnosis is critical for patient management and public health responses.

Molecular diagnostic tests on the other hand, utilize advanced molecular techniques such as polymerase chain reaction (PCR) and nucleic acid amplification to detect the influenza virus's genetic material directly. These tests offer high sensitivity and specificity, enabling early and accurate identification of viral infections. The increasing adoption of molecular diagnostic tests is driven by their ability to detect multiple flu strains and their potential to differentiate between seasonal and novel influenza viruses.

Breakup by Type of Flu:

Type A Flu

Type B Flu

Type C Flu

Type A Flu dominates the market

The report has provided a detailed breakup and analysis of the market based on the type of flu. This includes type A flu, type B flu, and type C flu. According to the report, type A flu represented the largest segment.

"Type A Flu" includes various influenza viruses, some responsible for seasonal flu outbreaks and potential pandemics. Accurate differentiation of specific Type A strains is essential for targeted treatment and surveillance efforts.

Furthermore, "Type B Flu" encompasses a distinct group of viruses contributing to seasonal flu epidemics. Detecting and categorizing Type B strains aid in tailoring medical interventions and vaccine development to mitigate flu-related complications.

Moreover, "Type C Flu," although typically milder, still requires accurate diagnosis for effective patient management. While it is less likely to cause large outbreaks, its inclusion highlights the comprehensive approach to influenza diagnostics.

Breakup by End User:

Hospitals

Diagnostic Laboratories

Others

Hospitals dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostic laboratories, and others. According to the report, hospitals represented the largest segment.

Hospitals encompass a significant portion of the market demand, offering immediate access to diagnostic services for patients with flu-like symptoms. Timely diagnosis within hospitals enables rapid treatment decisions and infection control measures, which are crucial for managing patient health and preventing virus spread within healthcare facilities.

Furthermore, diagnostic Laboratories are specialized hubs for accurate and thorough flu testing. These laboratories often employ advanced equipment and experienced personnel to conduct comprehensive diagnostic procedures. By focusing on high-quality diagnostics, they support healthcare providers in delivering accurate results, essential for effective patient management and public health interventions.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America's emphasis on research and innovation fosters the development of cutting-edge diagnostic technologies and methodologies. This region leads in adopting advanced testing solutions that enhance the accuracy and efficiency of flu detection. Its high prevalence of chronic diseases and respiratory conditions underscores the need for accurate influenza diagnostics. With a focus on timely detection, healthcare providers in North America rely on a wide range of diagnostic tests to ensure prompt treatment and prevent escalating flu-related complications.

Government initiatives, awareness campaigns, and strong healthcare policies drive the demand for influenza diagnostics. The region's robust public health infrastructure emphasizes the importance of accurate diagnostics in managing seasonal outbreaks and potential pandemics. The prevalence of international travel and globalization also heightens the demand for accurate flu testing in North America, as early detection becomes crucial in preventing the importation and spread of viral strains. The region's commitment to accurate and timely diagnostics positions it as a key driver in shaping the industry's expansion.

Competitive Landscape:

Top companies are bolstering the market through their innovative approaches and expertise. These companies leverage their resources and research capabilities to drive market expansion. They invest significantly in research and development, leading to the creation of advanced diagnostic technologies. These innovations, including AI-powered platforms and rapid testing solutions, enhance the accuracy and efficiency of flu detection. Top companies collaborate with healthcare providers and institutions to ensure widespread product access. These partnerships facilitate the integration of cutting-edge diagnostic solutions into existing healthcare systems, expanding market reach. Moreover, these companies often conduct awareness campaigns to educate healthcare professionals and the public about the importance of timely flu testing. These efforts drive increased demand for accurate diagnostics. Furthermore, their global presence and distribution networks enable them to provide essential diagnostic tools to regions with varying levels of healthcare infrastructure, contributing to overall market growth.

The report has provided a comprehensive analysis of the competitive landscape in the influenza diagnostics market. Detailed profiles of all major companies have also been provided.

Abbott Laboratories

Becton Dickinson and Company

Coris Bioconcept

Danaher Corporation

DiaSorin S.p.A.

F. Hoffmann-La Roche Ltd (Roche Holding AG)

Hologic Inc.

Meridian Bioscience Inc.

Qiagen N.V

Quidel Corporation

Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)

Siemens Healthineers AG (Siemens AG).

Recent Developments:

In August 2020, Abbott launched the BinaxNOW COVID-19 Ag Card, a rapid antigen test for detecting SARS-CoV-2, the virus causing COVID-19.

In August 2020, BD received Emergency Use Authorization from the FDA for a rapid point-of-care antigen test to detect SARS-CoV-2, providing results in 15 minutes.

In April 2020, Cepheid, a subsidiary of Danaher, received FDA Emergency Use Authorization for its Xpert Xpress SARS-CoV-2 test, designed to deliver rapid results for detecting COVID-19.

Key Questions Answered in This Report

  • 1. What was the size of the global influenza diagnostics market in 2023?
  • 2. What is the expected growth rate of the global influenza diagnostics market during 2024-2032?
  • 3. What are the key factors driving the global influenza diagnostics market?
  • 4. What has been the impact of COVID-19 on the global influenza diagnostics market?
  • 5. What is the breakup of the global influenza diagnostics market based on the product?
  • 6. What is the breakup of the global influenza diagnostics market based on the test type?
  • 7. What is the breakup of the global influenza diagnostics market based on type of flu?
  • 8. What is the breakup of the global influenza diagnostics market based on the end user?
  • 9. What are the key regions in the global influenza diagnostics market?
  • 10. Who are the key players/companies in the global influenza diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Test Kit and Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Test Type

  • 7.1 Molecular Diagnostic Tests
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction
      • 7.1.2.2 Isothermal Nucleic Acid Amplification Tests
      • 7.1.2.3 Other Molecular Tests
    • 7.1.3 Market Forecast
  • 7.2 Traditional Diagnostic Tests
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Rapid Influenza Diagnostic Tests
      • 7.2.2.2 Viral Culture Tests
      • 7.2.2.3 Direct Fluorescent Antibody Test
      • 7.2.2.4 Serological Tests
    • 7.2.3 Market Forecast

8 Market Breakup by Type of Flu

  • 8.1 Type A Flu
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type B Flu
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Type C Flu
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Coris Bioconcept
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 DiaSorin S.p.A.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd (Roche Holding AG)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Meridian Bioscience Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Qiagen N.V
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Quidel Corporation
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Siemens Healthineers AG (Siemens AG)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis